Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ALDX Stock Summary
Top 10 Correlated ETFs
ALDX
In the News
Aldeyra: Derisked Biotech Eyeing Path To Approval And Finalizing Deal With AbbVie
Lead asset, reproxalap, has clear path to regulatory approval in Dry Eye Disease. Option deal for commercial license with AbbVie signed - $400M in milestones, 60/40 profit shares of US market and tiered double-digit royalties for ex-US. $142M in cash at 12/31/23, burning $40M per year - plenty of cash to achieve monetization of reproxalap.
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Here, we discuss some reasons why investing in Aldeyra Therapeutics (ALDX) stock now may turn out to be a prudent move.
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunctivitis. The company has an option agreement with AbbVie, indicating strategic M&A value and potential for a takeover. ALDX's current market cap of $181.76 million is mostly its cash value of $144.33 million, making it a strong buy with significant upside potential.
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of ADX‑629 in patients with atopic dermatitis. The dial-in numbers are (888) 415-4305 for domestic callers and (646) 960-0336 for international callers. The access code is 5858366. A live audio webcast of the conference call also will be accessib.
Should You Buy Aldeyra Therapeutics (ALDX) Ahead of Earnings?
Aldeyra Therapeutics (ALDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BOX Gears Up to Report Q3 Earnings: What's in the Offing?
BOX's fiscal third-quarter results are likely to reflect strength in content cloud solutions.
Invest In Penny Stocks? Is It Worth It & 4 To Watch Now
If you're looking for penny stocks to invest in right now, you've got your work cut out for you. That's because the initial strategy when approaching cheap stocks is to trade them in the short term instead of holding them forever.
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures.
Why Are Stocks Up Today?
Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Committee (FOMC) meeting taking place today will result in an update to the interest rates that strongly affect the stock market.
ALDX Financial details
ALDX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -2.24 | -1.11 | -1.1 | -1.05 | -0.64 | |
Operating cash flow per share | -1.66 | -1.1 | -0.79 | -0.97 | -0.51 | |
Free cash flow per share | -1.66 | -1.1 | -0.79 | -0.97 | -0.51 | |
Cash per share | 2.71 | 2.29 | 4.25 | 2.98 | 2.42 | |
Book value per share | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | |
Tangible book value per share | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | |
Share holders equity per share | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | |
Interest debt per share | 0.57 | 0.51 | 0.33 | 0.3 | 0.3 | |
Market cap | 157.52M | 233.01M | 216.17M | 406.51M | 206.89M | |
Enterprise value | 127.85M | 170.48M | 2.24M | 278.17M | 79.72M | |
P/E ratio | -2.59 | -6.2 | -3.65 | -6.62 | -5.51 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -3.5 | -6.21 | -5.08 | -7.18 | -6.82 | |
PFCF ratio | -3.5 | -6.21 | -5.08 | -7.18 | -6.82 | |
P/B Ratio | 3.28 | 3.92 | 1.05 | 2.69 | 1.73 | |
PTB ratio | 3.28 | 3.92 | 1.05 | 2.69 | 1.73 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.33 | -4.97 | -0.04 | -4.61 | -1.87 | |
EV to operating cash flow | -2.84 | -4.55 | -0.05 | -4.91 | -2.63 | |
EV to free cash flow | -2.84 | -4.55 | -0.05 | -4.91 | -2.63 | |
Earnings yield | -0.39 | -0.16 | -0.27 | -0.15 | -0.18 | |
Free cash flow yield | -0.29 | -0.16 | -0.2 | -0.14 | -0.15 | |
Debt to equity | 0.31 | 0.26 | 0.08 | 0.11 | 0.13 | |
Debt to assets | 0.2 | 0.18 | 0.07 | 0.09 | 0.11 | |
Net debt to EBITDA | 0.54 | 1.82 | 3.82 | 2.13 | 2.99 | |
Current ratio | 5.82 | 6.69 | 19.77 | 11.78 | 6.44 | |
Interest coverage | -104.45 | -19.13 | -32.27 | -37 | -20.66 | |
Income quality | 0.74 | 1 | 0.74 | 0.91 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.1 | 0 | -0.03 | -0.06 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 9.46 | 6.6 | 9.69 | 7.82 | 5.4 | |
ROIC | -0.98 | -0.48 | -0.26 | -0.37 | -0.32 | |
Return on tangible assets | -0.81 | -0.45 | -0.25 | -0.34 | -0.25 | |
Graham Net | 1.95 | 1.84 | 4.32 | 2.48 | 1.94 | |
Working capital | 62.26M | 70.65M | 220.98M | 165.66M | 121.09M | |
Tangible asset value | 48.08M | 59.51M | 205.74M | 151.01M | 119.8M | |
Net current asset value | 47.73M | 59.22M | 205.35M | 150.74M | 114.81M | |
Invested capital | 0.31 | 0.26 | 0.08 | 0.11 | 0.13 | |
Average receivables | 14M | 26.5M | 75M | 64.12M | 1.62M | |
Average payables | 1.93M | 594.97K | 700.67K | 576.66K | 735.84K | |
Average inventory | -14M | -24.1M | -72.6M | -64.12M | -1.62M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 3.06K | 2.48K | 1.41K | 188.53 | 1.86K | |
Days of inventory on hand | -106.12K | -131.18K | -172.7K | -4.57K | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.12 | 0.15 | 0.26 | 1.94 | 0.2 | |
Inventory turnover | 0 | 0 | 0 | -0.08 | 0 | |
ROE | -1.27 | -0.63 | -0.29 | -0.41 | -0.31 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.01 | |
Net income per share | -0.21 | -0.25 | -0.15 | -0.14 | -0.08 | |
Operating cash flow per share | -0.19 | -0.16 | -0.23 | -0.14 | 0.01 | |
Free cash flow per share | -0.19 | -0.16 | -0.23 | -0.14 | 0.01 | |
Cash per share | 2.98 | 2.81 | 2.58 | 2.43 | 2.41 | |
Book value per share | 2.59 | 2.33 | 2.21 | 2.09 | 2.02 | |
Tangible book value per share | 2.59 | 2.33 | 2.21 | 2.09 | 2.02 | |
Share holders equity per share | 2.59 | 2.33 | 2.21 | 2.09 | 2.02 | |
Interest debt per share | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | |
Market cap | 406.51M | 583.8M | 493.26M | 394.05M | 207.78M | |
Enterprise value | 278.17M | 434.88M | 357.74M | 266.9M | 80.61M | |
P/E ratio | -8.39 | -9.78 | -13.72 | -12.03 | -10.93 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 529.21 | |
POCF ratio | -36.19 | -61.82 | -36.93 | -49.1 | 415.19 | |
PFCF ratio | -36.25 | -61.82 | -36.93 | -49.1 | 415.19 | |
P/B Ratio | 2.69 | 4.25 | 3.8 | 3.2 | 1.73 | |
PTB ratio | 2.69 | 4.25 | 3.8 | 3.2 | 1.73 | |
EV to sales | 0 | 0 | 0 | 0 | 205.32 | |
Enterprise value over EBITDA | -22.36 | -28.75 | -42.61 | -35.2 | -13.37 | |
EV to operating cash flow | -24.77 | -46.05 | -26.78 | -33.26 | 161.08 | |
EV to free cash flow | -24.8 | -46.05 | -26.78 | -33.26 | 161.08 | |
Earnings yield | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | |
Free cash flow yield | -0.03 | -0.02 | -0.03 | -0.02 | 0 | |
Debt to equity | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | |
Debt to assets | 0.09 | 0.1 | 0.1 | 0.11 | 0.11 | |
Net debt to EBITDA | 10.32 | 9.85 | 16.14 | 16.77 | 21.08 | |
Current ratio | 11.78 | 10.5 | 9.96 | 6.81 | 6.44 | |
Interest coverage | -29.72 | -34.2 | -19.62 | -17.73 | -11.86 | |
Income quality | 0.87 | 0.6 | 1.49 | 0.98 | -0.11 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0.01 | |
Payout ratio | 0 | 0 | 0 | 0 | -0.22 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 4.58 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 10.95 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0.24 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | -2.04 | |
Graham number | 3.47 | 3.65 | 2.76 | 2.55 | 1.91 | |
ROIC | -0.08 | -0.1 | -0.09 | -0.08 | -0.02 | |
Return on tangible assets | -0.07 | -0.09 | -0.06 | -0.06 | -0.03 | |
Graham Net | 2.48 | 2.28 | 2.14 | 2.02 | 1.93 | |
Working capital | 165.66M | 152.01M | 139.87M | 125.59M | 121.09M | |
Tangible asset value | 151.01M | 137.24M | 129.88M | 123.01M | 119.8M | |
Net current asset value | 150.74M | 137.04M | 129.75M | 122.94M | 114.81M | |
Invested capital | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | |
Average receivables | 12.37M | 1.63M | 11.84K | 0 | 0 | |
Average payables | 720.28K | 281.66K | 350.25K | 259.01K | 792.63K | |
Average inventory | -12.37M | -1.63M | -11.84K | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 180.46 | 577.43 | 378.83 | 342.27 | 1.81K | |
Days of inventory on hand | -4.38K | -31.83 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.5 | 0.16 | 0.24 | 0.26 | 0.05 | |
Inventory turnover | -0.02 | -2.83 | 0 | 0 | 0 | |
ROE | -0.08 | -0.11 | -0.07 | -0.07 | -0.04 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ALDX Frequently Asked Questions
What is Aldeyra Therapeutics, Inc. stock symbol ?
Aldeyra Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol ALDX
What is Aldeyra Therapeutics, Inc. stock quote today ?
Aldeyra Therapeutics, Inc. stock price is $3.259 today.
Is Aldeyra Therapeutics, Inc. stock public?
Yes, Aldeyra Therapeutics, Inc. is a publicly traded company.